AU 011Alternative Names: AU-011
Latest Information Update: 29 Sep 2015
At a glance
- Originator Aura Biosciences; National Cancer Institute (USA)
- Developer Aura Biosciences
- Mechanism of Action Immunostimulants; Reactive oxygen species stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Uveal melanoma